TY  - JOUR
AU  - Kaulen, Leon
AU  - Martinez-Lage, Maria
AU  - Abramson, Jeremy S
AU  - Karschnia, Philipp
AU  - Doubrovinskaia, Sofia
AU  - Shankar, Ganesh M
AU  - Choi, Bryan D
AU  - Ramundo, Christopher M
AU  - Ehret, Felix
AU  - Barnes, Jeffrey A
AU  - El-Jawahri, Areej
AU  - Hochberg, Ephraim P
AU  - Johnson, P Connor
AU  - Soumerai, Jacob D
AU  - Plotkin, Scott R
AU  - Batchelor, Tracy T
AU  - Wick, Wolfgang
AU  - Maus, Marcela V
AU  - Chen, Yi-Bin
AU  - Frigault, Matthew J
AU  - Dietrich, Jorg
TI  - Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.
JO  - Blood
VL  - 146
IS  - 16
SN  - 0006-4971
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2025-02156
SP  - 1902 - 1913
PY  - 2025
N1  - #EA:B320#
AB  - Tumor inflammation-associated neurotoxicity (TIAN) was recently proposed as a unique complication of immunotherapy in patients with brain tumor. Here, we report a first comprehensive characterization of TIAN in patients with central nervous system (CNS) lymphoma (CNSL) treated with CD19-directed chimeric antigen receptor (CD19-CAR) T cells. TIAN occurred in 10 of 56 (17.9
KW  - Humans
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Antigens, CD19: immunology
KW  - Immunotherapy, Adoptive: adverse effects
KW  - Central Nervous System Neoplasms: therapy
KW  - Central Nervous System Neoplasms: immunology
KW  - Central Nervous System Neoplasms: pathology
KW  - Aged
KW  - Adult
KW  - Neurotoxicity Syndromes: etiology
KW  - Neurotoxicity Syndromes: therapy
KW  - Lymphoma: therapy
KW  - Lymphoma: immunology
KW  - Lymphoma: pathology
KW  - Receptors, Chimeric Antigen: immunology
KW  - Treatment Outcome
KW  - Cytokine Release Syndrome: etiology
KW  - Antigens, CD19 (NLM Chemicals)
KW  - Receptors, Chimeric Antigen (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40663771
DO  - DOI:10.1182/blood.2025028964
UR  - https://inrepo02.dkfz.de/record/305427
ER  -